Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction (COOPERATION)
ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection
About this trial
This is an interventional prevention trial for ST-segment Elevation Myocardial Infarction (STEMI) focused on measuring ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous coronary intervention, Dexmedetomidine, Cardioprotection
Eligibility Criteria
Inclusion Criteria: the enrolled subjects must meet all of the following criteria:
- Aged 18-75 years old (inclusive);
- Diagnosed with anterior STEMI within 6h of symptom onset: (1) ischemic chest discomfort; (2) electrocardiogram (ECG) with ST elevation ≥0.2 mV in 2 or more contiguous precordial leads (one of which should be V2, V3, or V4);
- Sign the informed consent form.
Exclusion Criteria: subjects who meet any one of the following criteria are excluded from the study:
- Ventricular fibrillation, cardiogenic shock, Killip III-IV grade;
- Sinus bradycardia (heart rate sustained <60 beats/min), PR interval> 240ms or II-III degree atrioventricular block;
- Continuous systolic blood pressure <120mmHg;
- Severe breathing difficulties, aterial blood oxygen saturation <92%;
- Thrombolytic therapy has been performed before the first medical contact in the hospital;
- Consciousness disorder or past cerebrovascular disease;
- Previous history of myocardial infarction or PCI/CABG treatment;
- Known severe liver and kidney dysfunction;
- Known allergy to dexmedetomidine;
- CMR contraindications: such as claustrophobia, pacemaker or ICD implantation;
- Pregnant or lactating women;
- Malignant tumor or expected survival time <1 year;
- Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study (eg, poor compliance, inability of the patient to comply with study procedures and/or follow up);
- Participate in other randomized controlled studies at the same time.
Sites / Locations
- The First Affiliated Hospital of Anhui Medical UniversityRecruiting
- The First Affiliated Hospital of Lanzhou UniversityRecruiting
- The Second Affiliated Hospital of Harbin Medical UniversityRecruiting
- Mudanjiang Cardiovascular HospitalRecruiting
- Henan Provincial People's HospitalRecruiting
- Wuhan Asia Heart HospitalRecruiting
- Shaanxi Provincial People's HospitalRecruiting
- Shanxi Cardiovascular HospitalRecruiting
- Tianjin First Central HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Dexmedetomidine (DEX) group
Placebo (Saline) group
The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX group.